Evaluating the role of human papillomavirus vaccine in cervical cancer prevention

2004 ◽  
Vol 13 (2) ◽  
pp. 139-155 ◽  
Author(s):  
Minhee Kang ◽  
Stephen W Lagakos
2018 ◽  
Vol 122 ◽  
pp. 92-97 ◽  
Author(s):  
Giorgio Bogani ◽  
Umberto Leone Roberti Maggiore ◽  
Mauro Signorelli ◽  
Fabio Martinelli ◽  
Antonino Ditto ◽  
...  

2008 ◽  
Vol 34 (1) ◽  
pp. 65-84 ◽  
Author(s):  
Tracy Solomon Dowling

Merck’s recently released vaccine, Gardasil, may revolutionize cervical cancer prevention. With the rate of detected cervical cancer cases and associated deaths rising rapidly, cervical cancer is a major public health concern. Infection with the human papillomavirus, a sexually transmitted disease, is a necessary cause of cervical cancer. Gardasil protects against two specific “high risk” strains of HPV, associated with about 70% of cervical cancer cases, and blocks infection by two other strains of HPV, responsible for 90% of genital warts cases. Proponents of Gardasil believe that vaccination of women between the ages of 12 and 26 can slow the spread of cervical cancer by eradicating the two major HPV strands associated with the cancer’s development.


Sign in / Sign up

Export Citation Format

Share Document